Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
235.00
-0.57 (-0.24%)
At close: Jan 8, 2026, 4:00 PM EST
234.20
-0.80 (-0.34%)
After-hours: Jan 8, 2026, 7:37 PM EST
Danaher Revenue
Danaher had revenue of $6.05B in the quarter ending September 26, 2025, with 4.40% growth. This brings the company's revenue in the last twelve months to $24.27B, up 21.16% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$24.27B
Revenue Growth
+21.16%
P/S Ratio
6.94
Revenue / Employee
$385,206
Employees
63,000
Market Cap
165.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
| Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
| Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
| Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
| Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
| Dec 31, 2019 | 17.91B | 862.00M | 5.06% |
| Dec 31, 2018 | 17.05B | 1.53B | 9.86% |
| Dec 31, 2017 | 15.52B | -1.36B | -8.08% |
| Dec 31, 2016 | 16.88B | 2.45B | 16.97% |
| Dec 31, 2015 | 14.43B | 1.57B | 12.18% |
| Dec 31, 2014 | 12.87B | -5.42B | -29.62% |
| Dec 31, 2013 | 18.28B | 22.70M | 0.12% |
| Dec 31, 2012 | 18.26B | 2.17B | 13.49% |
| Dec 31, 2011 | 16.09B | 3.54B | 28.21% |
| Dec 31, 2010 | 12.55B | 2.03B | 19.33% |
| Dec 31, 2009 | 10.52B | -2.18B | -17.17% |
| Dec 31, 2008 | 12.70B | 1.67B | 15.16% |
| Dec 31, 2007 | 11.03B | 1.56B | 16.48% |
| Dec 31, 2006 | 9.47B | 1.59B | 20.26% |
| Dec 31, 2005 | 7.87B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DHR News
- 12 hours ago - Danaher Is Ready to Put Its Post-Covid Malaise Behind It - Barrons
- 3 days ago - Danaher to Present at J.P. Morgan Healthcare Conference - PRNewsWire
- 6 days ago - Top 15 High-Growth Dividend Stocks For January 2026 - Seeking Alpha
- 12 days ago - The Value Traps Of The REIT Sector - Seeking Alpha
- 15 days ago - HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 22 days ago - Danaher Schedules Fourth Quarter 2025 Earnings Conference Call - PRNewsWire
- 4 weeks ago - Danaher: Biotech Strength And Cash Generation Reinforce A $250 Fair Value - Seeking Alpha
- 4 weeks ago - Danaher Announces Quarterly Dividend - PRNewsWire